成人脊柱融合手术围手术期抗纤溶药物的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入11项随机对照试验共937例成人脊柱融合手术患者,比较围手术期使用与不使用抗纤溶药物的结局。抗纤溶药物与术中失血量、总失血量及输血发生率显著降低相关,术后血红蛋白显著更高,手术时间、总体并发症和住院时间无显著差异。作者认为抗纤溶药物可能有效且安全,但需进一步更大规模研究验证。
要点
- 纳入11项随机对照试验共937例成人脊柱融合手术患者,472例(50%)使用抗纤溶药物。
- 抗纤溶药物与术中失血量(MD -127.08 mL;P=0.002)和总失血量(MD -229.76 mL;P<0.00001)显著降低相关。
- 抗纤溶药物与输血发生率显著降低相关(OR 0.58;P=0.04),术后血红蛋白显著更高(MD 0.30 g/dL;P=0.02)。
核心结论
- 基于目前最高级别的比较证据,成人脊柱融合手术围手术期使用抗纤溶药物减少失血的可能性并非不合理,因其似乎既有效又安全。
- 作者认为除需进一步更大规模研究验证本研究发现外,成本效益分析和长期随访等实践方面将增进理解。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA指南进行系统评价。
- 电子数据库检索共识别2041条记录供筛选。
- 最终纳入11项随机对照试验,共937例成人脊柱融合手术患者。
- 472例(50%)患者接受抗纤溶药物治疗,其中345例(73%)接受氨甲环酸,127例(27%)接受ε-氨基己酸。
主要发现
- 抗纤溶药物组术中失血量显著低于对照组(MD -127.08 mL;P=0.002)。
- 抗纤溶药物组总失血量显著低于对照组(MD -229.76 mL;P<0.00001)。
- 抗纤溶药物组输血发生率显著低于对照组(OR 0.58;P=0.04)。
- 抗纤溶药物组术后血红蛋白显著高于对照组(MD 0.30 g/dL;P=0.02)。
- 手术时间(P=0.50)、总体并发症(P=0.21)和住院时间(P=0.88)在抗纤溶药物使用与否间无显著差异。
关键数值与推荐
- 评估结局包括术中失血量、总失血量、输血发生率、手术时间、总体并发症、住院时间、术后血红蛋白及其他血液学参数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需进一步更大规模研究验证本研究发现的相关性。
- 作者认为成本效益分析和长期随访等实践方面有待纳入以增进理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Systematic review and meta-analysis. OBJECTIVE: Compare outcomes of adult patients undergoing spinal fusion surgery who receive and do not receive perioperative antifibrinolytics to reduce operative blood loss. SUMMARY OF BACKGROUND DATA: The clinical potential for antifibrinolytics such as tranexamic acid and epsilon aminocaproic acid to significantly reduce blood loss during adult spinal fusion surgery remains underexplored. Outcomes for assessment included operative blood loss, and other surgical, clinical, and haematological outcomes. METHODS: We followed the recommended Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews. Electronic database searches identified 2041 for screening. Data were extracted and analyzed using meta-analysis of proportions. RESULTS: A total of 11 randomized controlled trials with a total of 937 adult spinal fusion surgery patients were included for analysis. There were 472 (50%) patients who were treated with antifibrinolytics, with 345 of 472 (73%) and 127 of 472 (27%) receiving tranexamic acid and epsilon aminocaproic acid respectively. The use of antifibrinolytics was associated with significantly lower intraoperative (MD -127.08 mL; P = 0.002) and total blood loss (MD -229.76 mL; P < 0.00001), as well as incidence of blood transfusion (OR 0.58; P = 0.04). There was no significant difference with antifibrinolytic use in terms of many surgical parameters, including surgery duration (P = 0.50), overall complications (P = 0.21), and length of stay (P = 0.88). Finally, postoperative haemoglobin was significantly greater (MD 0.30 g/dL; P = 0.02) following antifibrinolytic use, with other haematological parameters mostly unaffected. CONCLUSION: Based on the highest level comparative evidence available, the possibility for blood loss reduction in adult spinal fusion surgery with the use of perioperative antifibrinolytics is not unreasonable, as it appears both efficacious and safe. In addition to further, larger investigations to validate the associations found in this study, practical aspects such as cost-benefit analysis, and long-term follow-up will further enhance our understanding. LEVEL OF EVIDENCE: 1.
引用
- Lu VM, Ho YT, Nambiar M, et al. The Perioperative Efficacy and Safety of Antifibrinolytics in Adult Spinal Fusion Surgery: A Systematic Review and Meta-analysis. Spine (Phila Pa 1976). 2018. PMID: 30063223. doi:10.1097/BRS.0000000000002580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。